Peripheral Neuropathic Pain is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Peripheral Neuropathic Pain have a 88.89% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Peripheral Neuropathic Pain compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Peripheral Neuropathic Pain overview

Peripheral neuropathic pain refers to a type of chronic pain arising from damage or dysfunction to the peripheral nerves, causing altered or abnormal signaling to the brain. Conditions like diabetic neuropathy, post-herpetic neuralgia, or nerve compression injuries commonly lead to this form of pain. Symptoms encompass sensations of burning, tingling, shooting, or stabbing pain, often accompanied by heightened sensitivity in the affected area. Diagnosis involves a thorough medical history, neurological examinations, and sometimes nerve conduction studies. Treatment strategies typically include medications such as anticonvulsants, antidepressants, topical agents, physical therapy, and lifestyle modifications, focusing on managing symptoms and improving the individual’s quality of life.

For a complete picture of PTSR and LoA scores for drugs in Peripheral Neuropathic Pain, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.